UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange...
false000163605000016360502022-02-112022-02-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
0001636050false3/312022Q3.50.5033.3300016360502021-04-012021-12-3100016360502022-02-08xbrli:shares00016360502021-12-31iso4217:USD00016360502021...
Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
false000163605000016360502022-02-092022-02-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a...
– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first...
false000163605000016360502022-01-192022-01-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
0001636050false3/312022Q2.50.5033.3300016360502021-04-012021-09-30xbrli:shares00016360502021-11-10iso4217:USD00016360502021-09-3000016360502021...
– Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement...
false000163605000016360502021-11-112021-11-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.